A 26-Week Open-label Safety and Tolerability Extension Study of SEP-363856 in Adult Subjects with Schizophrenia
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2017
At a glance
- Drugs SEP 363856 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Sunovion Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 02 Feb 2017 Status changed from not yet recruiting to recruiting.
- 13 Jan 2017 Planned initiation date changed from 1 Dec 2016 to 1 Feb 2017.